S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
OrthoPediatrics Corp. (NASDAQ:KIDS), a company specializing in medical devices for pediatric orthopedics, has seen its stock price touch a 52-week low, reaching $20.26. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 6.98 and operates with moderate debt levels. This downturn reflects a significant retreat from better-performing periods, with the stock experiencing a 1-year change of -30.04%. Despite the price decline, the company has demonstrated robust revenue growth of 37.65% over the last twelve months. Investors are closely monitoring the company’s performance, as the current price level could signal both a potential concern for long-term prospects and an opportunity for those betting on a rebound, with analyst price targets suggesting significant upside potential. The market will be watching for OrthoPediatrics’ strategic responses to these challenges in the coming quarters, with the next earnings report expected on April 30, 2025. For deeper insights into KIDS’s financial health and growth prospects, access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, OrthoPediatrics Corporation reported its fourth-quarter 2024 earnings, revealing a revenue of $52.7 million, which surpassed expectations and marked a 40% year-over-year increase. However, the company faced a deeper-than-expected loss, with an EPS of -$0.69 compared to the forecasted -$0.30. JMP analysts maintained a Market Outperform rating for OrthoPediatrics, citing the company’s continued market share growth and a significant 52% increase in U.S. sales. The firm reiterated its guidance for 2025, expecting revenue growth between 15%-18% and adjusted EBITDA ranging from $15 million to $17 million.
OrthoPediatrics also announced the launch of its new VerteGlide Spinal Growth Guidance System for treating Early Onset Scoliosis, which has received FDA clearance. Lake Street Capital Markets initiated coverage on the company’s stock with a Buy rating and a $37 price target, highlighting its strong potential for growth and a unique market position. Conversely, Stifel adjusted the stock’s price target to $32, down from $40, while maintaining a Buy rating, following a positive earnings call. The company is expected to experience high-teens revenue growth in the coming years, according to Stifel’s analysis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.